Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
New approach for AF shows promise: Far-field antifibrillation - field electrodes delivering a short train of low-intensity electric pulses at the frequency of anti-tachycardia pacing - can terminate atrial fibrillation without the side effects of traditional high-voltage AF cardioversion, a canine study published in the August 11 issue of Circulation shows. The study was led by Flavio Fenton, Ph.D., Cornell University, and Stefan Luther, Ph.D., Planck Institute in Gottingen, Germany. In the study, the far-field approach terminated AF in 93% of attempts by generating wave emission sites within the tissue. "Further studies are needed to determine whether this marked reduction in energy can increase the effectiveness and safety for terminating atrial tachyarrhythmias clinically," the authors conclude
You may also be interested in...
FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
FDA is contributing $1.5 million to a large, collaborative clinical study designed to find out the optimum length of time to give anti-clotting drugs to patients with coronary drug-eluting stents
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.